Neurological complications in patients receiving CAR T-cell therapies

Authors

DOI:

https://doi.org/10.46765/2675-374X.2025v7n1e324

Keywords:

Cellular Therapies, ICANS, Non-ICANS Complications

Abstract

Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 or B cell maturation antigen has revolutionized the treatment of patients with relapsed lymphoma, acute lymphoblastic leukemia, and multiple myeloma. However, this therapy is associated with both short- and long-term immune-mediated toxicities. Among them, neurological complications represent a distinct and clinically significant category, with a wide range of presentations. In this paper, we describe the different types of immune effector cell–associated neurotoxicity syndrome (ICANS) and non-ICANS neurological toxicities, including their clinical features, recommended diagnostic evaluations, underlying mechanisms, and available treatment approaches.

References

1. Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, Urbano-Ispizua Á, Esteve J, Velasco-Hernandez T, Menéndez P. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10(1):210. https://doi.org/10.1038/s41392-025-02269-w DOI: https://doi.org/10.1038/s41392-025-02269-w

2. Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, Maude SL, McCarthy PL, Mead E, Neelapu SS, Neilan TG, Santomasso BD, Shpall EJ, Teachey DT, Turtle CJ, Whitehead T, Grupp SA. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020;8(2):e001511. https://doi.org/10.1136/jitc-2020-001511 DOI: https://doi.org/10.1136/jitc-2020-001511

3. Penack O, Peczynski C, Boreland W, Wolff D, Moiseev I, Schoemans H, Koenecke C, Graham C, Peric Z. Management of complications of chimeric antigen receptor T-cell therapy: a report by the European Society of Blood and Marrow Transplantation. Haematologica. 2024;109(11):3557-65. https://doi.org/10.3324/haematol.2023.284810 DOI: https://doi.org/10.3324/haematol.2023.284810

4. Clé DV, Donadel CD, Calado RT. CAR-T in resource-limited regions. Blood Global Hematology. 2025; 2(1): 100051. https://doi.org/10.1016/j.bglo.2025.100051 DOI: https://doi.org/10.1016/j.bglo.2025.100051

5. Graham CE, Velasco R, Alarcon Tomas A, Stewart OP, Dachy G, Del Bufalo F, Doglio M, Henter JI, Ortí G, Peric Z, Roddie C, van de Donk NWCJ, Frigault MJ, Ruggeri A, Onida F, Sánchez-Ortega I, Yakoub-Agha I, Penack O. Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee. Lancet Oncol. 2025;26(4):e203-e13. https://doi.org/10.1016/s1470-2045(24)00715-0 DOI: https://doi.org/10.1016/S1470-2045(24)00715-0

6. Vonberg FW, Malik I, O’Reilly M, Hyare H, Carr AS, Roddie C. Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy. J Neurol Neurosurg Psychiatry. 2025;96(7):665-78. https://doi.org/10.1136/jnnp-2024-333924 DOI: https://doi.org/10.1136/jnnp-2024-333924

7. Gust J, Taraseviciute A, Turtle CJ. Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs. 2018;32(12):1091-101. https://doi.org/10.1007/s40263-018-0582-9 DOI: https://doi.org/10.1007/s40263-018-0582-9

8. Zhu Y, Liu K, Rosen ST, Liu W, Zhu H. Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis. EClinicalMedicine. 2025;84:103267. https://doi.org/10.1016/j.eclinm.2025.103267 DOI: https://doi.org/10.1016/j.eclinm.2025.103267

9. Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, Dahiya S, Beitinjaneh AM, Jacobs MT, Mcguirk JP, Vose JM, Goy A, Andreadis C, Hill BT, Dorritie KA, Oluwole OO, Deol A, Paludo J, Shah B, Wang T, Banerjee R, Miklos DB, Rapoport AP, Lekakis L, Ghobadi A, Neelapu SS, Lin Y, Wang ML, Jain MD. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2023;41(14):2594-606. https://doi.org/10.1200/jco.22.01797 DOI: https://doi.org/10.1200/JCO.22.01797

10. Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, Hansen D, Ferreri C, Freeman CL, Afrough A, Anderson LD Jr, Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison MJ, Kitali A, Landau H, Mirza AS, Patwardhan P, Qazilbash M, Usmani S, Patel K, Nishihori T, Ganguly S, Pasquini MC. Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. Blood. 2025;146(2):167-77. https://doi.org/10.1182/blood.2024026216 DOI: https://doi.org/10.1182/blood.2024026216

11. Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O’Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L; ROCCA Consortium. Outcomes after brexucabtagene autoleucel administered as a standard therapy for adults with relapsed/refractory B-Cell ALL. J Clin Oncol. 2025;43(5):558-66. https://doi.org/10.1200/jco.24.00321 DOI: https://doi.org/10.1200/JCO.24.00321

12. Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705-16. https://doi.org/10.1056/nejmoa2024850 DOI: https://doi.org/10.1056/NEJMoa2024850

13. Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS; TRANSFORM Investigators. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022; 399 (10343):2294-308. https://doi.org/10.1016/s0140-6736(22)00662-6 DOI: https://doi.org/10.1016/S0140-6736(22)00662-6

14. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O’Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398 (10297): 314-24. https://doi.org/10.1016/s0140-6736(21)00933-8 DOI: https://doi.org/10.1016/S0140-6736(21)00933-8

15. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-52. DOI: https://doi.org/10.1016/S0140-6736(20)31366-0

16. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25(4): 625-38. https://doi.org/10.1016/j.bbmt.2018.12.758 DOI: https://doi.org/10.1016/j.bbmt.2018.12.758

17. Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel HG, Sadelain M, Brentjens RJ. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958-71. https://doi.org/10.1158/2159-8290.cd-17-1319 DOI: https://doi.org/10.1158/2159-8290.CD-17-1319

18. Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, Haris M, Wilson NE, Liu F, Gabunia K, Scholler J, Montine TJ, Bhoj VG, Reddy R, Mohan S, Maillard I, Kriegstein AR, June CH, Chang HY, Posey AD Jr, Satpathy AT. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell. 2020;183(1):126-42.e17. https://doi.org/10.1016/j.cell.2020.08.022 DOI: https://doi.org/10.1016/j.cell.2020.08.022

19. Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, Chen J, Chung D, Harju-Baker S, Özpolat T, Fink KR, Riddell SR, Maloney DG, Turtle CJ. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017;7(12):1404-19. https://doi.org/10.1158/2159-8290.cd-17-0698 DOI: https://doi.org/10.1158/2159-8290.CD-17-0698

20. Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501-21. https://doi.org/10.1038/s41571-024-00903-0 DOI: https://doi.org/10.1038/s41571-024-00903-0

21. Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat Rev Clin Oncol. 2021;18(11):715-27. https://doi.org/10.1038/s41571-021-00530-z DOI: https://doi.org/10.1038/s41571-021-00530-z

22. Pennisi M, Sanchez-Escamilla M, Flynn JR, Shouval R, Alarcon Tomas A, Silverberg ML, Batlevi C, Brentjens RJ, Dahi PB, Devlin SM, Diamonte C, Giralt S, Halton EF, Jain T, Maloy M, Mead E, Palomba ML, Ruiz J, Santomasso B, Sauter CS, Scordo M, Shah GL, Park JH, Yanez San Segundo L, Perales MA. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021;5(17):3397-406. https://doi.org/10.1182/bloodadvances.2020003885 DOI: https://doi.org/10.1182/bloodadvances.2020003885

23. Gomez-Llobell M, Serra Smith C, Gómez-Costas D, Gómez-Centurión I, García Domínguez JM, Escudero-Vilaplana V, Fernández Bullido Y, Carbonell D, Pion M, Bailén R, Gil-Perotin S, Martínez Ginés ML, Revuelta-Herrero JL, Fernández-Caldas P, Fernández VAP, Collado-Borrell R, Bastos-Oreiro M, Villanueva-Bueno C, García-Sanz R, Kwon M. ICANS risk model in CD19 CAR-T therapy: insights from profiling. Bone Marrow Transplant. 2025;60(10):1351-60. https://doi.org/10.1038/s41409-025-02679-y DOI: https://doi.org/10.1038/s41409-025-02679-y

24. Larue M, Bouvier A, Maillard A, Cuffel A, Allain V, Ursu R, Carpentier AF, Azoulay E, Thieblemont C, Di Blasi R, Caillat-Zucman S. Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy. J Immunother Cancer. 2024;12(9):e009525. https://doi.org/10.1136/jitc-2024-009525 DOI: https://doi.org/10.1136/jitc-2024-009525

25. Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-Cell therapy: ASCO Guideline. J Clin Oncol. 2021;39(35):3978-92. https://doi.org/10.1200/jco.21.01992 DOI: https://doi.org/10.1200/JCO.21.01992

26. Pensato U, Pondrelli F, de Philippis C, Asioli GM, Crespi A, Buizza A, Mannina D, Casadei B, Maffini E, Straffi L, Marcheselli S, Zinzani PL, Bonifazi F, Guarino M, Bramanti S. Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy. Neurol Sci. 2024;45(8):4007-14. https://doi.org/10.1007/s10072-024-07481-0 DOI: https://doi.org/10.1007/s10072-024-07481-0

27. Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141(20):2430-42. https://doi.org/10.1182/blood.2022017414 DOI: https://doi.org/10.1182/blood.2022017414

28. Gutierrez C, Brown ART, Herr MM, Kadri SS, Hill B, Rajendram P, Duggal A, Turtle CJ, Patel K, Lin Y, May HP, Gallo de Moraes A, Maus MV, Frigault MJ, Brudno JN, Athale J, Shah NN, Kochenderfer JN, Dharshan A, Beitinjaneh A, Arias AS, McEvoy C, Mead E, Stephens RS, Nates JL, Neelapu SS, Pastores SM. The chimeric antigen receptorintensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. J Crit Care. 2020;58:58-64. https://doi.org/10.1016/j.jcrc.2020.04.008 DOI: https://doi.org/10.1016/j.jcrc.2020.04.008

29. Gutierrez C, Brown ART, May HP, Beitinjaneh A, Stephens RS, Rajendram P, Nates JL, Pastores SM, Dharshan A, de Moraes AG, Hensley MK, Feng L, Brudno JN, Athale J, Ghosh M, Kochenderfer JN, Arias AS, Lin Y, McEvoy C, Mead E, Westin J, Kostelecky N, Mian A, Herr MM. Critically ill patients treated for chimeric antigen receptor-related toxicity: a multicenter study. Crit Care Med. 2022;50(1):81-92. https://doi.org/10.1097/ccm.0000000000005149 DOI: https://doi.org/10.1097/CCM.0000000000005149

30. Andersen L, Quinn RJ, Difilippo H, Garfall AL, Porter DL, Meghani SH, Deng J. Long-term quality of life, cognitive function, and symptom burden among chimeric antigen receptor T-cell recipients and associated cytokine release syndrome and neurotoxicity. JCO Oncol Pract. 2026;22(1):131-40. https://doi.org/10.1200/OP-24-00823 DOI: https://doi.org/10.1200/OP-24-00823

31. Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C, Frey NV, Landsburg DJ. Prolonged neurologic symptoms following immune effector cell-associated neurotoxicity syndrome in patients with large B-cell lymphoma treated with chimeric antigen receptormodified T cell therapY. Transplant Cell Ther. 2025;31(4):228-35. https://doi.org/10.1016/j.jtct.2025.01.884 DOI: https://doi.org/10.1016/j.jtct.2025.01.884

32. Kaulen LD, Martinez-Lage M, Abramson JS, Karschnia P, Doubrovinskaia S, Shankar GM, Choi BD, Ramundo CM, Ehret F, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Soumerai JD, Plotkin SR, Batchelor TT, Wick W, Maus MV, Chen YB, Frigault MJ, Dietrich J. Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy. Blood. 2025;146(16):1902-13. https://doi.org/10.1182/blood.2025028964 DOI: https://doi.org/10.1182/blood.2025028964

33. Mahdi J, Dietrich J, Straathof K, Roddie C, Scott BJ, Davidson TB, Prolo LM, Batchelor TT, Campen CJ, Davis KL, Gust J, Lim M, Majzner RG, Park JR, Partap S, Ramakrishna S, Richards R, Schultz L, Vitanza NA, Wang LD, Mackall CL, Monje M. Tumor inflammation-associated neurotoxicity. Nat Med. 2023;29(4):803-10. https://doi.org/10.1038/s41591-023-02276-w DOI: https://doi.org/10.1038/s41591-023-02276-w

34. Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, Teruya-Feldstein J, Crary JF, Fowkes ME, Stacy CB, Kim-Schulze S, Rahman A, Laganà A, Brody JD, Merad M, Jagannath S, Parekh S. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27(12):2099-103. https://doi.org/10.1038/s41591-021-01564-7 DOI: https://doi.org/10.1038/s41591-021-01564-7

35. Couturier A, Escoffre M, Leh F, Villoteau AS, Palard X, Le Jeune F, Decaux O, Lamy T, Houot R. Parkinsonlike neurotoxicity in female patients treated with idecabtagene-vicleucel. Hemasphere. 2024; 8(7): e131. https://doi.org/10.1002/hem3.131 DOI: https://doi.org/10.1002/hem3.131

36. Ho M, Paruzzo L, Noll JH, Stella F, Devi P, Ndeupen S, Day YA, Chen GM, Cohen IJ, Ramirez-Fernandez A, Waxman A, Kapur S, Chen F, Xu R, Huff A, Jarocha D, Patel V, Bochi-Layec AC, Ramasubramanian R, Liu S, Bouvier R, de Souza VB, Patel H, Li Z, Carturan A, Michener P, Hopkins CR, Koucky O, Minehart J, Dimitri A, Nabar NR, Hasanali ZS, Ciccarelli BT, Hung P, Williams E, Bartoszek R, Lavorando M, Mohan S, Gonzalez VE, Porazzi P, Bhoj VG, Apostolidis SA, Vogl DT, Porter DL, Scholler J, Diorio C, Roche AM, Everett JK, Bushman FD, Nathanson KL, Stadtmauer EA, Susanibar-Adaniya SP, Garfall AL, Ruella M, Cohen AD, Fraietta JA. CD4(+) T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy. Nat Med. 2026;32(2):702-16. https://doi.org/10.1038/s41591-025-04121-8 DOI: https://doi.org/10.1038/s41591-025-04121-8

37. Rodríguez-Otero P, Sidana S, Kouwenhoven M, Schecter JM, Lendvai N, De Braganca KC, Slaughter A, Lonardi C, Vlummens P, Varsos H, Corsale C, Madduri D, Zhao H, Li K, Lee E, Marquez L, Zhao M, Yeh TM, Chen D, Plaks V, Montes de Oca R, Florendo E, Patel N, Akram M, Koneru M, Santomasso BD, Gállego Perez-Larraya J, van de Donk NW. Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4. Blood Cancer J. 2025;15(1):209. https://doi.org/10.1038/s41408-025-01410-w DOI: https://doi.org/10.1038/s41408-025-01410-w

38. Lemoine J, Bachy E, Cartron G, Beauvais D, Gastinne T, Di Blasi R, Rubio MT, Guidez S, Mohty M, Casasnovas RO, Joris M, Castilla-Llorente C, Haioun C, Hermine O, Loschi M, Carras S, Bories P, Fradon T, Herbaux C, Sesques P, Le Gouill S, Morschhauser F, Thieblemont C, Houot R. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Blood Adv. 2023; 7(21): 6589-98. https://doi.org/10.1182/bloodadvances.2023010624 DOI: https://doi.org/10.1182/bloodadvances.2023010624

39. Cordas dos Santos DM, Tix T, Shouval R, Gafter-Gvili A, Alberge JB, Cliff ERS, Theurich S, von Bergwelt- Baildon M, Ghobrial IM, Subklewe M, Perales MA, Rejeski K. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024;30(9):2667-78. https://doi.org/10.1038/s41591-024-03084-6 DOI: https://doi.org/10.1038/s41591-024-03084-6

40. Natrajan K, Kaushal M, George B, Kanapuru B, Theoret MR. FDA Approval summary: ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. Clin Cancer Res. 2024;30(14):2865-71. https://doi.org/10.1158/1078-0432.ccr-24-0378 DOI: https://doi.org/10.1158/1078-0432.CCR-24-0378

41. Jhaveri KS, Schlam I, Holtzman NG, Peravali M, Richardson PK, Dahiya S, Malkovska V, Rapoport AP. Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy. Blood Adv. 2020;4(23):6019-22. https://doi.org/10.1182/bloodadvances.2020003176 DOI: https://doi.org/10.1182/bloodadvances.2020003176

42. Kilroe KM, Clarke JE, Ann P, Salamon N, Acharya J. Guillain-Barre syndrome in patients receiving chimeric antigen receptor T-cell therapy: an individual participant data meta-analysis. Front Neurol. 2025; 16: 1704826. https://doi.org/10.3389/fneur.2025.1704826 DOI: https://doi.org/10.3389/fneur.2025.1704826

43. Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, Russo D, Auclair R, Fitzgerald L, Cadzin B, Wang X, Sikder D, Senechal B, Bermudez VP, Purdon TJ, Hosszu K, McAvoy DP, Farzana T, Mead E, Wilcox JA, Santomasso BD, Shah GL, Shah UA, Korde N, Lesokhin A, Tan CR, Hultcrantz M, Hassoun H, Roshal M, Sen F, Dogan A, Landgren O, Giralt SA, Park JH, Usmani SZ, Rivière I, Brentjens RJ, Smith EL. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387(13):1196-206. https://doi.org/10.1056/nejmoa2209900 DOI: https://doi.org/10.1056/NEJMoa2209900

Downloads

Published

10/14/2026

How to Cite

Jiang, J., Battistin, V., Lima, M. de, & Cottini, F. (2026). Neurological complications in patients receiving CAR T-cell therapies. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 7(1). https://doi.org/10.46765/2675-374X.2025v7n1e324

Issue

Vol. 7 No. 1 (2026): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Cellular Therapy Manual

License

Copyright (c) 2026 Justin Jiang, Virginia Battistin, Marcos de Lima, Francesca Cottini

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Funding data